Evidence map›Paper›PMID 34152533›Full record

ArticleInternational journal of clinical oncology2021

Incurable locoregional disease is a strong poor prognostic factor in recurrent or metastatic squamous cell carcinoma of the head and neck.

Ari Nishimura, Tomoya Yokota, Satoshi Hamauchi, Yusuke Onozawa, Hiromichi Shirasu, Takanori Kawabata, Hirofumi Ogawa, Tsuyoshi Onoe, Yoshiyuki Iida, Takashi Mukaigawa and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Ari NishimuraDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan.
Tomoya YokotaDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan. t.yokota@scchr.jp.ORCID http://orcid.org/0000-0001-7327-7949
Satoshi HamauchiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan.
Yusuke OnozawaDivision of Medical Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Hiromichi ShirasuDivision of Medical Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Takanori KawabataDepartment of Biostatistics, Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan.
Hirofumi OgawaDivision of Radiation Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Tsuyoshi OnoeDivision of Radiation Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Yoshiyuki IidaDivision of Head and Neck Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Takashi MukaigawaDivision of Head and Neck Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Hirofumi YasuiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan.
Shizuoka Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDistant metastasis is a poor prognostic factor in recurrent/metastatic squamous cell carcinoma of the head and neck. However, limited information on the prognostic impact of locoregional disease is available, despite its life-threatening features. We investigated the prognostic impact of incurable locoregional disease and distant metastasis in recurrent/metastatic squamous cell carcinoma of the head and neck.

methodsWe retrospectively analyzed 156 patients with recurrent/metastatic squamous cell carcinoma of the head and neck who received palliative chemotherapy between August 2006 and December 2019.

resultsThe median follow-up time for all censored patients was 12.1 (range 1.9-63.5) months. The median overall survival was 12.4 (95% confidence interval 10.1-15.1) months. Incurable locoregional disease (hazard ratio: 2.31, P = 0.007), liver metastasis (hazard ratio: 2.84, P = 0.006), disease-free interval > 13 months (hazard ratio: 0.51, P = 0.041), cetuximab use (hazard ratio: 0.59, P = 0.007), and immune checkpoint inhibitor use (hazard ratio: 0.56, P = 0.006) were associated with prognosis. The number of distant metastatic sites was not associated with overall survival (1-2: hazard ratio: 0.60, P = 0.16; 3-4: hazard ratio: 1.34, P = 0.50). Patients with incurable locoregional disease had more life-threatening events than those with curable locoregional disease.

conclusionThe presence of incurable locoregional disease had a significant prognostic impact, whereas the number of distant metastatic sites had no prognostic impact. Liver metastasis was a poor prognostic factor for recurrent/metastatic squamous cell carcinoma of the head and neck.

Indexed as

Head and Neck NeoplasmsHumansNeoplasm Recurrence, LocalPrognosisRetrospective StudiesSquamous Cell Carcinoma of Head and NeckDistant metastasisImmune checkpoint inhibitorIncurable locoregional diseaseNumber of distant metastatic sitesPrognostic factorRecurrent/metastatic squamous cell carcinoma of the head and neck

Identifiers

PMID34152533
OpenAlexW3176227046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.